No­var­tis’ Kisqali pre­vents breast can­cer from com­ing back for longer — but can it best Eli Lil­ly’s Verzenio? #AS­CO23

CHICA­GO — No­var­tis’ CDK4/6 in­hibitor Kisqali helped ear­ly breast can­cer pa­tients stay can­cer-free for longer af­ter surgery, ac­cord­ing to in­ter­im study re­sults pre­sent­ed at AS­CO. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER